Back to insights
Article/ Industry Insights
After a Patent Expires, What Actually Stops Anyone From Making the Molecule?
29 min read
After a Patent Expires, What Actually Stops Anyone From Making the Molecule?
The Reaction Interface Economy: the hidden supply chain behind pharmaceuticals, agrochemicals, and electronic materials
ChemAbout Insight · Reaction Interface Economy · Series hub
◆ KNOWLEDGE CARD — 5-minute overview
Before You Read
This piece is written for you if you are:
- Sourcing fine chemicals, pharmaceutical intermediates, or electronic-grade materials, and need to judge how replaceable a supplier actually is
- Building a case for a generic API, a post-patent agrochemical, or an import-substitution program, and need to know which layer the real barrier sits in
- Studying industry structure, supply-chain concentration, or export controls
- Learning chemistry, chemical engineering, or materials science, and want the part of the story that sits between "the molecule" and "the industry"
What you'll take away:
- Why there is an entire supply chain between "the patent expired" and "we can make it"
- Why a company that owns a molecule outright still spent $16.5 billion to get capacity
- What happened the one time a government actually used specialty chemicals as leverage over a chip industry — and why the result surprised almost everyone
- Where value actually stops on a chemical value chain: not on the molecule, not on the plant, but on the layer between them
One-Sentence Answer
The moat in specialty chemicals is not owning a molecule; it is controlling the reaction interface between a laboratory route and reliable industrial production — a layer that is written neither into the patent nor into the structural formula. Two checkable facts set the scale: the US FDA still maintains, and updates roughly every six months, a list of marketed drugs whose patents have expired and whose exclusivity has ended but for which no generic has ever been approved; and in 2024, Novo Nordisk — which owns semaglutide outright — was party to a $16.5 billion transaction to secure fill-finish capacity.
What is the Reaction Interface Economy?
The Reaction Interface Economy is the layer of value that sits between a molecule's public structure and its reliable industrial production. It is made of five capabilities that never appear in a structural formula:
- Process route — the development work between a synthesis that works and a process that runs
- Key intermediates — the one or two nodes that decide whether a route is viable and where the cost lands
- Scale-up experience — heat transfer, mass transfer, addition rates, and failure modes, re-established at every change of volume
- Impurity control — where impurities come from, in what order they are removed, and how you prove they stay removed
- Regulatory validation — registration pathway, change control, and a manufacturing record that survives an inspection
What defines this layer is that it can be fully captured by neither instrument: not by a patent, because most of it is not invention; and not by a specification sheet, because a spec records the result, not how the result is reached reliably. This series established the framework in an earlier piece on agrochemical intermediates; this article is its hub.
Knowledge Graph — the map first
MAIN LINE: where value stops
Molecular structure (public)
↓
Synthesis route (available once the patent lapses)
↓
Reaction interface (tacit industrial capability) ←── what this article is about
↓
Reliable supply (commercial value)
Reaction interface = process development · scale-up · impurity control
· batch consistency (CMC) · regulatory validation
PROCESS BRANCH: who can actually make it
Key starting material (KSM) → intermediate → building block
→ CDMO scale-up → API / technical grade → registration → formulation
TREND BRANCH: where this layer is heading
Excess capacity ←→ scarce process capability
Export controls ←→ certification lock-in
Chemical factory ──→ reaction-interface partner
Three paths, three questions: where value stops (main line), who can actually make it (process branch), and where this layer is heading (trend branch). The Deep Dive walks all three.
Mental Model
What you think you're buying: What you're actually buying:
a molecule a reaction history
│ │
a CAS number ┌────────────┴──────────────────┐
│ │ │
a structure written down: never written down:
│ the route catalyst lot-to-lot drift
a purity spec the equations addition rate, temperature curve
theoretical yield where impurities come from
failure modes that appear only at scale
ten years of operator judgement
└──────┬──────┘
▼
this layer is the reaction interface
it decides whether the same molecule
is the same product in two plants
The reframe in one line: a molecule can be made public; a reaction interface cannot — which is why this industry has never really traded structural formulas, only validated reaction histories.
◆ INSIGHT ARTICLE — 20–30 minute deep read
Deep Dive
1. Why do drugs with no patent still have no generic?
Fundamental ★★★★★ Must-read
Answer: not because nobody wants to make them, but because "legally permitted" and "industrially achievable" are two independent conditions — and the regulator says so on the record.
-
The FDA maintains a list specifically for drugs that face no legal barrier and still face no competitor. It is called the List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic (the OPOE list). It captures approved drug products whose patents have expired and whose exclusivity has ended, and for which the FDA has never approved an ANDA. It is updated roughly every six months and split in two: Part I covers products for which the FDA could accept an ANDA immediately; Part II covers products where legal, regulatory, or scientific questions should be resolved with the agency before submission. There are separate prescription and OTC versions.
-
The list's stated purpose rules out the easy explanation. The obvious objection is that these products simply have markets too small to bother with. But the FDA publishes the list precisely to improve transparency for products with limited competition and to encourage submissions through the abbreviated pathway. The regulator is not treating these as commercially dead; it is recording something plainer: the legal condition for entry has disappeared, and manufacturing, regulatory, or economic conditions may still keep competitors out. The list is the argument. If patent expiry meant contestability, it would be empty.
-
Research into shortages points at manufacturing quality and economics, not legal access. Woodcock and Wosinska, writing in Clinical Pharmacology & Therapeutics (2013), analysed shortages of US generic sterile injectables and concluded that manufacturing-quality problems combine with economic and technological factors to produce them — the core mechanism being that the market cannot observe and reward quality. When a buyer sees price and nothing else, price competition erodes the investments that are invisible, until a quality failure forces a shutdown, a recall, and a shortage.
The lead author was, at the time, the director of the FDA's Center for Drug Evaluation and Research. This is not outside criticism; it is the regulator's own account of why a patent-free market can still fail.
-
The same structure recurs in agrochemicals, on weaker evidence. A cluster of agrochemical active ingredients reaches its patent cliff between 2026 and 2028, and industry tallies put roughly 105 active ingredients as having lost protection between 2009 and 2023. But when the compound patent lapses, originators typically still hold a portfolio around it — process patents, key-intermediate patents, optical-isomer resolution patents, synergistic-mixture patents — and any one still standing can block a complete production route.
Patent expiry releases legal freedom, not manufacturing capability; the products on that list are the quietest possible evidence.
Procurement Insight: In supply-risk work on an off-patent product, what usually gets examined is not patent status but how many production lines are genuinely running worldwide, the outcome of the most recent regulatory inspection, and how many qualified sources exist for the key intermediates.
2. Why did a company that owns the molecule outright still pay $16.5 billion for capacity?
Industry ★★★★★ Must-read
Answer: because a key interface in the supply chain carries value independent of the molecule — ownership of a molecule and the ability to supply it are two assets that can be priced separately.
-
On 5 February 2024, Novo Nordisk announced an unusually structured transaction. Its controlling shareholder, Novo Holdings, acquired the CDMO Catalent for $16.5 billion; simultaneously, Novo Nordisk agreed to buy three of its fill-finish sites from Novo Holdings for $11 billion — in Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium — employing more than 3,000 people between them. The announcement stated the deal would gradually increase Novo Nordisk's filling capacity from 2026 onwards.
-
What matters is what this company was short of. Novo Nordisk owns the semaglutide molecule, its patents, its clinical data, and its trademarks. It is the most complete rights-holder that molecule has anywhere in the world. It was not short of the molecule, and not short of formulation knowledge. It was short of the capacity to put already-synthesised API into an injection pen.
To be precise about the claim: this interface is sterile fill-finish, not an intermediate — it sits at the far downstream end of the chain. So the example does not prove that "intermediates matter." It proves something more general: a key interface in a supply chain can be priced, traded, and bottlenecked independently of the molecule that passes through it.
More generally still: the reaction interface is not fixed at one point in the chain — it moves with the industry and the product type. In peptide drugs it can sit at both ends, on the synthesis route and on sterile fill-finish. In agrochemicals it usually sits on key starting materials and key intermediates. In electronic materials it sits on the photoacid generator, the polymer resin, and purification. Different positions, same nature: the stretch of capability that neither a patent nor a specification sheet fully captures. That is why one framework can carry three apparently unrelated industries.
-
For peptide drugs, this interface extends upstream into the synthesis route itself. Isidro-Llobet and co-workers, writing in The Journal of Organic Chemistry (2019, ACS), put the process mass intensity (PMI) of solid-phase peptide synthesis at roughly 3,000 to 15,000 kilograms of input per kilogram of API. That number is why peptide capacity is not simply expanded on demand: it is simultaneously a solvent-consumption, waste-treatment, and environmental-permitting problem. Fill-finish is the segment of this chain that got a public price; the synthesis route is the segment that did not, and constrains just as hard.
-
Molecular design has already been paying for synthesisability. Lau and co-workers' semaglutide discovery paper in the Journal of Medicinal Chemistry (2015) shows that its 31-residue length is an engineering trade-off from SAR optimisation, balancing activity against synthesisability — the current balance, not a demonstrated global optimum.
Every choice made in molecular design is eventually paid for on the plant floor — and Novo Nordisk's share of that bill came to $11 billion.
Engineering Insight: The transaction draws a clean line. A synthesis route can be written down, transferred, and reproduced. The capacity, validation state, and regulatory history of a sterile filling line cannot — it can only be built or bought.
⚠️ This article contains no medical or dosing content. Finished GLP-1 drugs are patented prescription medicines and are outside ChemAbout's listable scope; what the platform covers is the legitimate upstream reagent layer (Fmoc-OSu, HATU, and similar peptide coupling and protecting reagents).
3. Why does the same end product have different cost curves at different companies?
Industry ★★★★☆ Advanced reading
Answer: because an identical end molecule does not imply an identical path to it — the cost divergence happens at the intermediate, not at the last step.
-
Glyphosate is the clearest specimen for watching this. Mainstream industrial routes generally converge on the same key intermediate node — PMIDA (N-phosphonomethyliminodiacetic acid) — reached by way of IDA (iminodiacetic acid). There is one end molecule and several ways upstream of it, and the real cost divergence between producers happens at the step of how IDA is obtained, which sets the raw-material structure, the energy structure, and the waste structure.
-
A reaction step can be patented on its own. The subject of US 7,799,571 and US 11,802,835 is not the glyphosate molecule — that has long been unclaimable — but how to control the conversion of PMIDA to glyphosate. It is a directly checkable illustration: once a molecule enters the public domain, patent protection migrates upstream and comes to rest on a reaction step.
-
One intermediate feeding a whole product family is the norm, not a coincidence. A single pyridine intermediate can feed four neonicotinoid insecticides; a single pyrazole acid can feed an entire family of SDHI fungicides. Capacity and price movements at the intermediate therefore transmit simultaneously into end markets that look unrelated.
On a chemical value chain, patents migrate upstream as the molecule lapses, and settle on the reaction step that can be neither designed around nor disclosed.
Market Insight: The price curve of a technical-grade active ingredient and the price curve of its key intermediate are frequently out of phase. The window in which they diverge is usually the window in which an upstream capacity constraint is doing the work.
4. What the Japan–Korea materials dispute showed: supply leverage comes from certification lock-in, not market share
Advanced ★★★★★ Must-read
Answer: three materials were restricted the same way and the results were completely different — and that asymmetry identifies the source of supply leverage more precisely than any market-share figure.
-
In July 2019, Japan imposed individual export licensing on three semiconductor materials bound for South Korea: hydrogen fluoride (HF), photoresist, and fluorinated polyimide. This was not an embargo. Bulk licences were replaced by contract-by-contract individual licences, requiring exporters to declare end user, product specification, and technical information for each shipment. It is one of the few public, measurable experiments in chemical supply leverage in modern industrial history.
-
The three materials behaved nothing alike. According to trade-data analysis published by Japan's Research Institute of Economy, Trade and Industry (RIETI) and by CEPR, Japanese HF exports to Korea fell by 96.8%, while photoresist and fluorinated polyimide showed no comparable decline — partly because Japan's Ministry of Economy, Trade and Industry granted three-year bulk licences for some photoresist transactions in December 2019. Korea shifted part of its sourcing to Belgium, the United States, and Taiwan.
-
The asymmetry is the finding. If supply leverage came from market share, three similarly concentrated materials should have behaved alike. They did not. The difference lies in something more specific: how many alternative sources exist at the required purity grade, how long a fab requalification takes, and whether the line keeps running while that requalification is underway. In other words, leverage comes from certification lock-in, not from share — and certification lock-in is what the reaction interface is called in electronic materials.
-
It also explains why an advanced material is not "a product." A photoresist is a formulated system of polymer resin, photoacid generator (PAG), quencher, and solvent, each component qualified separately. Certification lock-in is not lock-in to a supplier; it is lock-in to a formulation having been validated on one specific line.
-
The same mechanism goes by a different name in regulated pharmaceutical intermediates. In electronic materials, the thing locked in is a fab's line qualification. In APIs and key intermediates, it is registration dossiers, site registrations, and change-control history — call it regulatory lock-in. What both share is that the cost of switching suppliers is set not by the price of the material but by the time required to prove all over again that the new source is usable.
A real control experiment did not show that whoever holds the material holds the industry. It showed that "can this be substituted?" has to be answered separately for every single material.
Procurement Insight: In due diligence on semiconductor, display, and pharmaceutical-grade materials, the question pressed is rarely a supplier's global share. It is the requalification period needed to switch, how the existing line runs during that period, and whether a second source has already completed equivalent validation.
5. Why is "we can make it" a different claim from "we can keep supplying it"?
Fundamental ★★★★☆ Advanced reading
Answer: because industrialisation is not graded on the first successful synthesis, but on batch-to-batch consistency under regulatory constraint.
-
The real manufacturing problem starts after the first success. A completed synthesis at bench or pilot scale proves the route is viable. Industrial supply has to prove that batch 50 sits in the same acceptable band as batch 1 on purity, impurity profile, and yield, and that the band does not drift across the supply period. Pharma calls this set of requirements CMC (chemistry, manufacturing, and controls); other parts of fine chemicals use other names for the same class of constraint.
-
These constraints are invisible, and therefore cannot be priced automatically. Back to the mechanism from section 1: when a buyer can observe price and a certificate of analysis but not process stability, equipment redundancy, or quality-system investment, price competition systematically erodes the investments nobody can see. A shortage is not necessarily the result of too little competition; it can be the result of competition on a single dimension.
-
The regulatory pathway is a threshold independent of patents. Compound patent expiry is not a registration exemption — a generic entrant still has to complete an independent approval process in every target market. This is why registration-service firms exist as a separate link in the chain, and part of why "patent expired" and "product on the market" are often years apart.
-
In sequence, compliance precedes procurement. Grade selection — research, technical, food, pharmaceutical, electronic — is not driven by price but derived backwards from the regulatory pathway of the target market. Higher purity is not automatically more suitable either: material whose purity does not match the specification filed in the dossier is equally unusable in a regulated application.
The line between suppliers is not "can they make it" but "can they make, in year three, batch seven, the same thing they made in batch one."
Procurement Insight: An RFQ for a key intermediate destined for regulated use typically asks for more than CAS number, purity, and price. It also asks for the items below — every one of which describes the reaction interface rather than the molecule:
- the production route, and whether it has changed in recent years
- whether the key starting material (KSM) is made in-house, single-sourced, or multi-sourced
- impurity-profile data across multiple batches, rather than a single-batch COA
- whether a second manufacturing site or a validated backup line exists
- how change control is managed and how customers are notified
- the site's history of regulatory inspections
6. Which layer is China's fine-chemical industry moving from, and to?
Trend ★★★☆☆ Trend reading
Answer: the policy text points from scale toward process capability and supply-chain security; the publicly verifiable evidence so far sits at the level of stated intent and individual company behaviour, not completed transition.
-
The policy text is unusually specific. The 14th Five-Year Plan for the Development of the Raw Materials Industry, issued jointly by China's Ministry of Industry and Information Technology, Ministry of Science and Technology, and Ministry of Natural Resources (MIIT Joint Planning No. 212 [2021], issued 21 December 2021), sets out five priority tasks: moving upmarket, rationalisation, green transition, digitalisation, and security. Under the security heading it states that autonomous control of key production process technologies and equipment in priority sectors is to improve substantially, and that break points and bottlenecks in industrial chains are to be markedly reduced.
Note where that language lands. It points at process technology, equipment, and chain break points — not at output or capacity.
-
The counter-evidence should not be skipped. Industry data providers report that Chinese capacity for certain agrochemical active ingredients now clearly exceeds real global field demand, with pyroxasulfone and S-metolachlor named among them. The risk of repeatedly betting on the same expiring molecule is real: capacity can be built quickly; process capability cannot.
-
So the honest description of this layer is a coexistence. Policy points explicitly at process autonomy and the elimination of break points, while parts of the sector still compete through capacity. Both are true at once, and they do not cancel out — they describe different segments of the same industry sitting in different places.
Scale can be built in a few years; a reaction interface cannot — which is roughly the true length of the road from "chemical factory" to "reaction-interface partner."
Market Insight: The observable markers of this transition are usually not capacity announcements or export totals, but whether backward integration into key starting materials is actually happening, and whether domestic firms are beginning to take on custom-synthesis work that requires long process validation.
7. What is the real question for a chemical buyer?
Industry ★★★★★ Must-read
Answer: the six sections above all push the same judgement to the same place — supply risk is not set by price or capacity, but by how much reaction interface would have to be rebuilt if this relationship broke.
-
Price and capacity describe a current state, not replaceability. A quotation and a capacity figure are both obtainable before a supplier change happens. What matters after it happens is whether a second source has already completed equivalent validation — and that item does not appear on a quotation.
-
Each of the six sections leaves behind a separately answerable question:
- how many qualified sources exist globally, as distinct from how many suppliers exist (section 1)
- where the key interface sits for this category: synthesis route, key intermediate, scale-up capacity, or fill-finish (section 2)
- at which step cost diverges, and whether end-product and intermediate prices move together (section 3)
- how long requalification takes, and how the line runs during it (section 4)
- what mechanism guarantees that batch seven in year three matches batch one (section 5)
-
These five share one property: none of the answers is in the molecule, and none is on the quotation. They describe the shape of the reaction interface — the layer of capability that is covered completely by neither a patent nor a specification. An RFQ will always surface a price; whether it surfaces replaceability depends on whether the party asking knows where that layer is.
-
To be explicit: the above is this article's own synthesis of the preceding six sections (
[D]), not a survey finding about procurement practice.
The unit of supply risk is not "how many suppliers" — it is "how long does it take to rebuild a reaction interface."
Procurement Insight: ChemAbout's aim is to build a knowledge infrastructure for chemical supply chains: so that what the market sees is not only a CAS number, but the supply capability, substitution paths, and industrial position behind that molecule. The platform describes supply-chain structure; it does not give procurement advice.
Industry Insight
Read the seven sections together and the map of this industry comes out differently from the intuition.
Chemistry organises knowledge around molecules: CAS numbers, structures, purity specs, patent numbers. But from the FDA's list of drugs with no generic, to the $11 billion Novo Nordisk paid for filling capacity, to the patents resting on the PMIDA conversion step, to a 2019 export control that bound on hydrogen fluoride and nothing else — every one of these points at the same location. Value does not stop on the molecule, and it does not stop on the plant. It stops on the layer between them. That layer is made of process development, scale-up experience, impurity control, batch consistency, and certification history. It is not in the patent, because it is not invention. It is not in the structure, because it is not structure. It exists only in the running record of one particular production line over several years.
That layer is what this series calls the Reaction Interface Economy. It does not explain one industry's quirk; it is the same mechanism developing three times independently — in pharmaceuticals as "off patent, still no generic"; in agrochemicals as "same end price, very different cost"; in electronic materials as "same share, different substitutability."
For anyone judging supply risk, the practical content of the framework is this: replaceability is not determined by the number of suppliers, but by how much reaction interface a switch would require rebuilding. For anyone judging industrial upgrading, it is this: capacity accrues in years, reaction interface accrues over product lifetimes — which is why the competitive order of a fine-chemical segment is never reshaped on the day a capacity expansion is announced.
What Surprised Us
Most people think: patent expiry opens the market, and whoever has capacity can enter. Reality: the FDA still maintains, and updates roughly every six months, a list of marketed drugs whose patents have expired and whose exclusivity has ended, and for which no generic has ever been approved. The list's existence is the proof that a patent is not the last gate.
Most people think: the company that holds the molecule holds the supply. Reality: Novo Nordisk, which owns semaglutide outright, was in 2024 party to a $16.5 billion transaction and paid $11 billion for three fill-finish sites. The molecule was never what it was short of.
Most people think: the more concentrated the market share, the stronger the chokehold. Reality: of the three materials Japan restricted to Korea in 2019, only hydrogen fluoride showed a collapse in exports — 96.8%. Photoresist and fluorinated polyimide did not. What decides whether leverage bites is certification lock-in, not share.
Continue Exploring
Upstream / intermediates
- Why does one chemical intermediate end up in dozens of pesticides? Inside the Reaction Interface Economy
- What's hardest to get after a patent expires isn't the patent — it's the intermediate
Process / manufacturing capability
- Why doesn't the chemical industry actually sell molecules?
- Why LAB became the backbone of global detergents
Downstream / electronic materials
- Why can only a handful of companies make top-tier OLED emitter materials?
- What are electronic resins? Materials and science
Trend
- China's fine chemicals: from capacity to process capability (forthcoming)
- CRO, CMO, CDMO: where the boundaries actually fall
Quick Answers
What is the Reaction Interface Economy? The Reaction Interface Economy is the hidden capability layer between a chemical molecule's public structure and its reliable industrial production — made up of process route, key intermediates, scale-up experience, impurity control, and regulatory validation. It explains why, once a molecule becomes public, the number of companies that can reliably supply it stays small.
Why do chemical intermediates matter? Because once the end molecule's structure and route are public information, intermediates are often what determine manufacturing feasibility, cost structure, and supplier replaceability. The molecule decides what gets made; the intermediate decides who can make it and where the cost lands.
Why doesn't patent expiry always create competition? Because patent expiry removes legal exclusivity, not process knowledge, regulatory history, or manufacturing capability. The US FDA still maintains a list of marketed drugs that are off patent, off exclusivity, and have no approved generic — updated roughly every six months.
How should supply-chain risk be measured? Not by the number of suppliers, but by switching cost — how much reaction interface a change of source would require rebuilding. In electronic materials this appears as certification lock-in; in regulated pharmaceutical intermediates it appears as regulatory lock-in.
Evidence Notes
Evidence grading (applied consistently across the ChemAbout article series) [A] Academic Literature — peer-reviewed academic journals. [B] Official Documents — official or legally authoritative records (regulatory filings, patent-office documents, and comparable legal documents). [C] Industry Sources — trade-association reports, company disclosures, or market research (including government research institutes and industry data providers). [D] ChemAbout Inference — reasoning specific to this article, built on [A]/[B]/[C] evidence above, not an independently verified result.
Key Facts
- The US FDA maintains the List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic (OPOE list), covering approved drug products off patent, off exclusivity, and with no approved ANDA; updated roughly every six months, split into Part I (ANDA acceptable immediately) and Part II (legal/regulatory/scientific questions to resolve with FDA before submission), with separate prescription and OTC versions. FDA's stated purpose is to improve transparency for products with limited competition and encourage submissions via the abbreviated pathway [B].
- Woodcock J, Wosinska M, Economic and technological drivers of generic sterile injectable drug shortages, Clinical Pharmacology & Therapeutics, 2013: manufacturing-quality problems combine with economic and technological factors to cause generic sterile injectable shortages; the core mechanism is that "the market cannot observe and reward quality" [A].
- Isidro-Llobet et al., The Journal of Organic Chemistry, 2019 (ACS): process mass intensity for solid-phase peptide synthesis is approximately 3,000–15,000 kg of input per kg of API [A].
- Lau et al., Journal of Medicinal Chemistry, 2015: semaglutide's 31-residue length is an engineering trade-off from SAR optimisation between activity and synthesisability; this article does not describe it as a demonstrated optimum [A].
- The claims of US 7,799,571 and US 11,802,835 concern methods of controlling the PMIDA conversion step in glyphosate manufacture, not the glyphosate molecule itself [B].
Industrial Map
- "Reaction Interface Economy" is an explanatory framework proposed by ChemAbout, not an established industry term; its definition (process route / key intermediates / scale-up experience / impurity control / regulatory validation) is given by this series [D].
- The interface involved in the Novo Nordisk–Catalent transaction is sterile fill-finish and drug product, which sits downstream and is not an intermediate step; this article uses it to argue that a key interface carries independent value, not to argue about intermediates as such [D].
- The reaction interface moves along the chain by product category (peptide drugs: synthesis route and sterile fill-finish; agrochemicals: KSM and key intermediates; electronic materials: PAG, polymer resin, and purification). This generalisation is made by this article [D].
- Mainstream glyphosate routes converge on IDA → PMIDA → glyphosate; cost divergence between producers occurs mainly on the IDA preparation path rather than the final step [D]. This article does not cite route-by-route capacity shares or step yields — available public sources are not of sufficient grade to support specific figures.
- A photoresist is a formulated system rather than a single product, comprising polymer resin, photoacid generator (PAG), quencher, and solvent, each qualified separately by the fab [D].
- One pyridine intermediate can supply multiple neonicotinoid insecticides; one pyrazole acid can supply the SDHI fungicide family [C].
- This article uses "certification lock-in" for the line-qualification barrier in electronic materials and "regulatory lock-in" for the registration and change-control barrier in regulated pharmaceutical intermediates; the latter is this article's framing, not a statutory term [D].
- The RFQ requirements listed in section 5 are a descriptive generalisation of common industry practice, not quoted from any single procurement standard [D].
- This article does not cite national or company market-share figures for photoresist — the available sources are secondary compilations of insufficient grade [D].
Regulatory Status
- Compound patent expiry is not a registration exemption: a generic entrant must still complete an independent approval process in every target market [D].
- In July 2019, Japan moved exports of hydrogen fluoride, photoresist, and fluorinated polyimide to South Korea from bulk to individual licensing; in December 2019, Japan's Ministry of Economy, Trade and Industry granted three-year bulk licences for some photoresist transactions [C].
- The 14th Five-Year Plan for the Development of the Raw Materials Industry was issued jointly by China's Ministry of Industry and Information Technology, Ministry of Science and Technology, and Ministry of Natural Resources (MIIT Joint Planning No. 212 [2021], 21 December 2021), setting out five priority tasks — upmarket, rationalisation, green, digital, and security — including substantially improved autonomous control of key production process technologies and equipment in priority sectors, and markedly reduced break points and bottlenecks in industrial chains [B].
- None of the molecules referenced in this article (semaglutide, glyphosate, and the named agrochemical active ingredients) is a Chemical Weapons Convention scheduled chemical. Finished GLP-1 drugs are patented prescription medicines and are outside the platform's listable scope [D].
Supply Chain Notes
- Novo Nordisk company announcement, 5 February 2024: Novo Holdings to acquire Catalent for $16.5 billion; Novo Nordisk to acquire from Novo Holdings three fill-finish sites in Anagni (Italy), Bloomington (Indiana, US), and Brussels (Belgium) for $11 billion, employing more than 3,000 people in total, expected to increase filling capacity gradually from 2026 onwards [C] (company disclosure).
- Following the export controls, Japanese hydrogen fluoride exports to South Korea fell 96.8%, while photoresist and fluorinated polyimide showed no comparable decline; South Korea shifted part of its sourcing to Belgium, the United States, and Taiwan [C] (trade-data analysis by RIETI and CEPR).
- Industry data providers report Chinese capacity for certain agrochemical active ingredients (including pyroxasulfone and S-metolachlor) clearly exceeding real global field demand [C] (third-party estimate).
- Roughly 105 agrochemical active ingredients lost patent protection between 2009 and 2023; a further cluster reaches expiry between 2026 and 2028 [C] (industry tallies; figures and reporting years vary somewhat between sources).
Sources & Method
- This article proposes no new theory. Its core theory remains the Reaction Interface Economy, established by this series in "Why does one chemical intermediate end up in dozens of pesticides?". This article is that framework's hub, gathering its evidence across pharmaceuticals, agrochemicals, and electronic materials in one place rather than naming a new "economy" for each phenomenon.
- Content marked [D] is reasoning made by this article on top of [A]/[B]/[C] evidence, not an independently verified result.
- Figures supported only by blogs, broker notes, or unattributed trade claims are excluded outright rather than retained behind hedged wording — this includes photoresist market shares and glyphosate route-by-route capacity shares and step yields.
- Written in July 2026. Patent expiry dates, transaction values, capacity data, and regulatory status all change over time.
Source References
Government / Regulatory
- FDA — List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic (Prescription)
- FDA — Over-the-Counter List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic
- USPTO — US 7,799,571: Control of N-(phosphonomethyl)iminodiacetic acid conversion in manufacture of glyphosate
- USPTO — US 11,802,835: Control of N-(phosphonomethyl)iminodiacetic acid conversion in manufacture of glyphosate
- 工业和信息化部 科学技术部 自然资源部关于印发"十四五"原材料工业发展规划的通知（工信部联规〔2021〕212号）
Academic
- Woodcock J, Wosinska M — Economic and technological drivers of generic sterile injectable drug shortages, Clin Pharmacol Ther 2013 (PubMed 23337525)
- The impact of export controls on international trade: Evidence from the Japan–Korea trade dispute in the semiconductor industry — Journal of the Japanese and International Economies
Industry / Trade Policy
- RIETI — The impact of export controls on international trade: Evidence from the Japan–Korea trade dispute in the semiconductor industry
- CEPR / VoxEU — The impact of export controls on international trade
- USITC Working Paper — The South Korea–Japan Trade Dispute in Context: Semiconductor Manufacturing, Chemicals, and Concentrated Supply Chains
Companies
